One approach to reactivate silenced NK cells in cHL is to employ the currently clinically available monoclonal antibodies, Nivolumab and Pembrolizumab, to block immune checkpoint PD-1 on activated CD4+ and CD8+ T-cells, and NK cells (97). This evidence concerns the gene CD4 and classic Hodgkin lymphoma.